We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
-9.64%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
–
Cap. Flow
+$1.17B
Cap. Flow %
100.06%
Top 10 Hldgs %
60.23%
Holding
42
New
42
Increased
–
Reduced
–
Closed
–

Top Buys

1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$143M
2
PHAT icon
Phathom Pharmaceuticals
PHAT
+$94.1M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$72.8M
4
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$67.2M
5
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$61.6M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 98.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRDS
26
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$15M 1.28%
+2,081,007
New +$20.5M
FLACU
27
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$15M 1.28%
+1,501,000
New +$14.9M
NTLA icon
28
Intellia Therapeutics
NTLA
$1.66B
$14.8M 1.26%
+203,684
New +$17.3M
STRO icon
29
Sutro Biopharma
STRO
$393M
$14.6M 1.24%
+177,648
New +$16.9M
TYRA icon
30
Tyra Biosciences
TYRA
$1.88B
$14.2M 1.21%
+1,327,665
New +$15.8M
REPL icon
31
Replimune Group
REPL
$799M
$12.2M 1.04%
+716,762
New +$13.5M
GRCL
32
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$8.03M 0.68%
+3,445,973
New +$11.7M
ACRS icon
33
Aclaris Therapeutics
ACRS
$749M
$7.04M 0.6%
+408,329
New +$5.57M
AVDL
34
DELISTED
Avadel Pharmaceuticals
AVDL
$6.5M 0.55%
+951,814
New +$6.54M
MTEM
35
DELISTED
Molecular Templates, Inc.
MTEM
$4.74M 0.4%
+91,603
New +$4.05M
EPIX
36
DELISTED
ESSA Pharma
EPIX
$4.28M 0.36%
+692,910
New +$6.09M
APTX
37
DELISTED
Aptinyx Inc. Common Stock
APTX
$4.28M 0.36%
+1,883,244
New +$5.64M
IMVT icon
38
Immunovant
IMVT
$8B
$3.23M 0.28%
+585,759
New +$3.65M
SRRK icon
39
Scholar Rock
SRRK
$6.2B
$2.01M 0.17%
+156,000
New +$2.67M
CERE
40
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.96M 0.17%
+55,835
New +$1.63M
EPZM
41
DELISTED
Epizyme, Inc
EPZM
$850K 0.07%
+739,369
New +$1.21M
NBRV
42
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$179K 0.02%
+17,026
New +$207K
1
2

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q1 2022 Portfolio in Review

Q1 2022 is the first quarter with a 13F filing on record for Frazier Life Sciences Management, which disclosed 42 positions worth $1.17B. Its ten largest holdings account for 60% of the portfolio.

Its largest position is Arcutis Biotherapeutics: 8,434,232 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets.

  • Frazier Life Sciences Management's largest Q1 2022 buy was Arcutis Biotherapeutics: 8,434,232 shares worth $162M.
  • Frazier Life Sciences Management's ten largest holdings make up 60% of its $1.17B portfolio in Q1 2022.
  • Frazier Life Sciences Management disclosed 42 positions in Q1 2022, its first 13F filing on record.

Based on Frazier Life Sciences Management's 13F filing for Q1 2022, filed 16 May 2022.